Myelofibrosis and anemia: A German claims data analysis to describe epidemiology and current treatment
The data reveal gaps in MF treatments and the need to improve patient quality of life.
Authors
- Florian M. Karl (ORCID: https://orcid.org/0000-0002-3155-4941)
- Sophia Junker (ORCID: https://orcid.org/0000-0002-1434-9380)
- Alexander Slowley (ORCID: https://orcid.org/0009-0003-6996-9709)
- Erika Gleißner
- Tim d'Estrube
- Kelesitse Phiri (ORCID: https://orcid.org/0000-0002-6847-0231)
- Joachim R. Göthert (ORCID: https://orcid.org/0000-0001-8957-6732)
- S. Mueller (ORCID: https://orcid.org/0000-0003-4889-3058)
- Sofie Weinmann
Institutions
- Wismar University of Applied Sciences (DE)
- Syneos Health (Germany) (DE)
- GlaxoSmithKline (United States) (US)
- Health Economics and Outcomes Research (United Kingdom) (GB)
- GlaxoSmithKline (Germany) (DE)
- West German Heart and Vascular Center Essen (DE)
Publication Details
- Journal
- European Journal Of Haematology
- Published
- 2024-08-05
- DOI
- https://doi.org/10.1111/ejh.14284
- Primary Topic
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- GlaxoSmithKline